← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

FDA approvalNew or expanded indicationRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant treatment of renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.

LAMPGEN ANALYSIS

Why it matters

The indication moves PD-1 inhibition into a postoperative renal cell carcinoma setting.

What research teams should watch

Reconcile resection and pathology reports and document recurrence risk, residual disease status and eligibility timing.

PRIMARY RECORDS

Sources